Document is current
Any future updates will be listed below
-
Authors
Lapi, Francesco https://orcid.org/0000-0002-4342-9128
Marconi, Ettore
Grattagliano, Ignazio
Cricelli, Claudio
-
Funding
Funding for this research was provided by:
Italian College of General Practitioners and Primary Care.
- License Information
-
More Information
Article History
Received: 6 March 2023
Accepted: 31 March 2023
First Online: 12 April 2023
Declarations
:
: FL and EM provided consultancies in protocol preparation for epidemiological studies and data analyses for Dompé, Angelini, Pfizer, and GSK. IG and CC provided clinical consultancies for Dompé, Angelini, Pfizer, and GSK.
: According to a by-law on the classification and implementation of observational drug-related research, as issued by the Italian National Drug Agency (an entity belonging to the Italian Ministry of Health), the present study does not require approval by an Ethics Committee in Italy (Italian Drug Agency note of 3 August 2007). This study followed the principles of the Declaration of Helsinki and compliant with the ENCePP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance) Guide on Methodological Standards in Pharmacoepidemiology.
: The database is fully anonymized.
: Not applicable.
Free to read: This content has been made available to all.
